Old ACTC news but always good to read again. I reposted in cause biel missed it.
Advanced Cell Technology's Q3 2013 Results - Earnings Call Transcript
In October, we held a meeting of our Ophthalmic Advisory Board, which includes some of the most highly respected physicians in the world, our team of clinical and regulatory consultants, and the senior management team of ACT. A couple of key takeaways from that meeting include no major safety concerns related to the cells in the treatment, clear signs of long-term engraftment and survival, and in many cases efficacy. In fact, during the one-year follow-up period, patients in both the Stargardt's and Dry AMD trials have shown improvement in visual acuity in their treated eye. Vision in one of the patients for example improved from 20/400 to 20/40 in the first month.